# A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

> **NCT06118866** · PHASE2 · COMPLETED · sponsor: **Hope Medicine (Nanjing) Co., Ltd** · enrollment: 192 (actual)

## Conditions studied

- Androgenetic Alopecia

## Interventions

- **DRUG:** placebo-Q2W
- **DRUG:** HMI-115-120mg-Q4W
- **DRUG:** HMI-115-240mg-Q4W
- **DRUG:** HMI-115, 240mg-Q2W

## Key facts

- **NCT ID:** NCT06118866
- **Lead sponsor:** Hope Medicine (Nanjing) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-11
- **Primary completion:** 2024-08-26
- **Final completion:** 2024-11-28
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06118866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06118866, "A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06118866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*